Use of lipid-, blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - jamanetwork.com
Importance Based on contemporary estimates in the US, evidence-based therapies for
cardiovascular risk reduction are generally underused among patients with type 2 diabetes …

Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial

NJ Pagidipati, AJ Nelson, LA Kaltenbach, M Leyva… - JAMA, 2023 - jamanetwork.com
Importance Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk
in adults with type 2 diabetes are underused in clinical practice. Objective To assess the …

Gaps in evidence‐based therapy use in insured patients in the united states with type 2 diabetes mellitus and atherosclerotic cardiovascular disease

AJ Nelson, M Ardissino, K Haynes… - Journal of the …, 2021 - Am Heart Assoc
Background Evidence‐based therapies are generally underused for cardiovascular risk
reduction; however, less is known about contemporary patients with type 2 diabetes mellitus …

Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease: insights from Getting to an …

SV Arnold, JA De Lemos, RS Rosenson… - Circulation, 2019 - Am Heart Assoc
In summary, in a large contemporary US cohort of patients with diabetes mellitus and
ASCVD, few patients received comprehensive guideline–recommended medical therapies …

Opportunities for improving use of evidence‐based therapy in patients with type 2 diabetes and cardiovascular disease

Y Gao, E Peterson, N Pagidipati - Clinical Cardiology, 2019 - Wiley Online Library
Evidence‐based therapy that target hyperlipidemia, hypertension, smoking cessation, and
weight loss have demonstrated significant benefits in reducing cardiovascular risks and …

Lipid-lowering therapies and cardiovascular risk-stratification strategies in adults with type 1 diabetes

NSR Lan, DA Bell, GF Watts… - Current Opinion in …, 2023 - journals.lww.com
Lipid-lowering therapies and cardiovascular risk-stratificat... : Current Opinion in
Endocrinology, Diabetes and Obesity Lipid-lowering therapies and cardiovascular risk-stratification …

Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study

SV Arnold, JA de Lemos, L Zheng… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To examine improvement in the use of optimal medical therapy (OMT) for secondary
prevention in patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes …

Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry

SV Arnold, K Gosch, M Kosiborod, ND Wong… - American Heart …, 2023 - Elsevier
Background Cardiovascular disease remains the primary source of morbidity and mortality
in type 2 diabetes (T2D). We characterized the change over time in the use of evidence …

Actionable real-world evidence to improve health outcomes and reduce medical spending among risk-stratified patients with diabetes

EM Garry, S Schneeweiss, S Eapen… - Journal of Managed …, 2019 - jmcp.org
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic condition with a high
economic burden as well as drug treatments that have not all demonstrated effects on …

The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States

W Weng, Y Tian, SX Kong, R Ganguly… - Endocrinology …, 2019 - Wiley Online Library
Objectives The purpose of this study was to assess atherosclerotic cardiovascular disease
(ASCVD) prevalence, antidiabetes medication usage and physician specialty encounters …